CN114222573A - 蛋白酶体核心颗粒的小分子刺激物 - Google Patents

蛋白酶体核心颗粒的小分子刺激物 Download PDF

Info

Publication number
CN114222573A
CN114222573A CN202080057165.6A CN202080057165A CN114222573A CN 114222573 A CN114222573 A CN 114222573A CN 202080057165 A CN202080057165 A CN 202080057165A CN 114222573 A CN114222573 A CN 114222573A
Authority
CN
China
Prior art keywords
substituted
heteroaryl
aryl
heteroarylalkyl
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080057165.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·特拉德
R·A·科尔曼
A·萨拉查-查帕罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN114222573A publication Critical patent/CN114222573A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080057165.6A 2019-08-16 2020-08-14 蛋白酶体核心颗粒的小分子刺激物 Pending CN114222573A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962887732P 2019-08-16 2019-08-16
US62/887,732 2019-08-16
PCT/US2020/046269 WO2021034627A1 (en) 2019-08-16 2020-08-14 Small molecule stimulators of the core particle of the proteasome

Publications (1)

Publication Number Publication Date
CN114222573A true CN114222573A (zh) 2022-03-22

Family

ID=74659522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080057165.6A Pending CN114222573A (zh) 2019-08-16 2020-08-14 蛋白酶体核心颗粒的小分子刺激物

Country Status (5)

Country Link
US (1) US20220267280A1 (https=)
EP (1) EP4013405A4 (https=)
JP (1) JP7583027B2 (https=)
CN (1) CN114222573A (https=)
WO (1) WO2021034627A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620881A (zh) * 2021-08-12 2021-11-09 浙江禾本科技股份有限公司 一种1-[2-(2,4-二氯苯基)-2羟基乙基]-1h咪唑的合成方法
WO2023036936A1 (en) 2021-09-09 2023-03-16 Booster Therapeutics Gmbh Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4147723A1 (en) 2021-09-09 2023-03-15 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
WO2025219559A1 (en) 2024-04-18 2025-10-23 Booster Therapeutics Gmbh Pyrrolidine compounds as proteasome stimulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022546A1 (ja) * 2002-09-04 2004-03-18 Keimei Oh ジャスモン酸の生合成を阻害する物質
CN101193859A (zh) * 2005-06-14 2008-06-04 先灵公司 蛋白酶抑制剂的制备和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
US3991202A (en) * 1974-01-31 1976-11-09 Janssen Pharmaceutica N.V. Imidazolium salts
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
EP0829478A3 (en) * 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
NZ328607A (en) * 1996-09-09 1999-08-30 Hoffmann La Roche Heterocyclically substituted n-benzyl-azolium derivatives and fungicidal compositions
BRPI0904249B1 (pt) * 2009-08-28 2018-03-06 Biolab Sanus Farmacêutica Ltda. Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica
US11197862B2 (en) * 2015-07-16 2021-12-14 Xomics Biopharma, Inc. Methods of preventing toxicity of platinum drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022546A1 (ja) * 2002-09-04 2004-03-18 Keimei Oh ジャスモン酸の生合成を阻害する物質
CN101193859A (zh) * 2005-06-14 2008-06-04 先灵公司 蛋白酶抑制剂的制备和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHIH-HSIUNG WU ET AL: "Antitumor Effects of Miconazole on Human Colon Carcinoma Xenografts in Nude Mice through Induction of Apoptosis and G0/G1 Cell Cycle Arrest", 《TOXICOLOGY AND APPLIED PHARMACOLOGY》, vol. 180, pages 22, XP093058971, DOI: 10.1006/taap.2002.9352 *
FERNANDA C. DE MORAES ET AL: "Quantification of dapaconazole in human plasma usinghigh-performance liquid chromatography coupled to tandem massspectrometry: Application to a phase I study", 《JOURNAL OF CHROMATOGRAPHY B》, vol. 958, pages 102 - 107 *
JACQUIE L HARPER ET AL: "Effect of calmidazolium analogs on calcium influx in HL-60 cells", 《BIOCHEMICAL PHARMACOLOGY》, vol. 60, no. 3, pages 317 - 324, XP093058506, DOI: 10.1016/S0006-2952(00)00349-X *
XIN LU ET AL: "Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2, 3-dioxygenase 1 (IDO1) inhibition: the design, synthesis of miconazole analogues targeting Alzheimer’s disease", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 26, no. 8, pages 1665 - 1674, XP055702914, DOI: 10.1016/j.bmc.2018.02.014 *
XIN LU ET AL: "Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: the design, synthesis of miconazole analogues targeting Alzheimer’s disease", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 26, no. 8, pages 1665 - 1674, XP055702914, DOI: 10.1016/j.bmc.2018.02.014 *

Also Published As

Publication number Publication date
JP7583027B2 (ja) 2024-11-13
WO2021034627A1 (en) 2021-02-25
JP2022544536A (ja) 2022-10-19
US20220267280A1 (en) 2022-08-25
EP4013405A4 (en) 2023-08-09
EP4013405A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
CN114222573A (zh) 蛋白酶体核心颗粒的小分子刺激物
ES2786298T3 (es) Inhibidores de benzimidazol del canal de sodio
EP3801500B1 (en) Inhibitors of sarm1
US20100168103A1 (en) Diaryl piperidine compounds as calcium channel blockers
EP3424912B1 (en) 2-aminothiazole derivatives, preparation and use thereof
EP3484863B1 (en) Cyclic amides as potassium channel openers
CN110559446A (zh) 靶向治疗学
CN107613965A (zh) 用于减少胃排空的方法和组合物
KR20120081119A (ko) 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체
EA021237B1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90
EP2828249B1 (en) Premature-termination-codons readthrough compounds
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
US6552060B1 (en) Asymmetric disulfides and methods of using same
US20100029681A1 (en) Heterocyclic compounds as calcium channel blockers
WO2017161004A1 (en) PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
US10441586B2 (en) CRMP2 SUMOylation inhibitors and uses thereof
US12060337B2 (en) Substituted dibenzo[b, f]azepines as proteasome activators
WO2023244682A1 (en) Methods and compounds for modulating inherited genetic diseases
US20060089363A1 (en) Antibacterial agents
WO2023205807A2 (en) Proteolysis targeting chimeras for human pregnane x receptor and for degradation of gspt1
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
EP3582766B1 (en) Pten binding compounds, formulations, and uses thereof
US20260092058A1 (en) Small Molecule Degraders and Fluorescent Probes of PXR
CN110545822A (zh) 药剂、组合物及其相关方法
JP2008533122A (ja) 新規なチロシン誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination